课题基金 / 基金详情

Development and Translation of D-glucose as a Diagnostic Agent for MRI of Cancer

Development and Translation of D-glucose as a Diagnostic Agent for MRI of Cancer
D-葡萄糖作为癌症 MRI 诊断剂的开发和转化
批准号:
8854375
负责人:
Peter CM Van Zijl
金额:
$116.3万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-05-01 至 2020-01-31
关键词:
AddressAdverse effectsAnatomyAnimal ModelAnimalsBiochemicalBiomedical EngineeringBiometryBlood VolumeBrain NeoplasmsCancer BiologyCause of DeathCellsCerebrumChemicalsClinicClinicalClinical OncologyCollaborationsComputer softwareContrast MediaDataData AnalysesDetectionDevelopmentDiabetes MellitusDiagnosticDisadvantagedDiseaseDoseEndocrinologyEngineeringEquipmentExtracellular SpaceFDA approvedGadoliniumGliomaGlucoseGlucose tolerance testGoalsHealthcareHumanHuman VolunteersHydroxyl RadicalHypoxiaImageImageryImaging technologyImplantIndustryInfusion proceduresInstitutesIntravenousIntravenous infusion proceduresIsotopesKidney DiseasesLabelLeadershipLegal patentLicensingMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMagnetismMalignant NeoplasmsMalignant neoplasm of brainMeasurementMeasuresMetabolismMetalsMethodologyMethodsMonitorMusNamesOutcomePatientsPerfusionPermeabilityPhysiologic pulsePhysiologicalPhysiologyPlayProceduresProcessPropertyProtocols documentationProtonsReportingResearchResearch InstituteResourcesRiskRoleSafetySensitivity and SpecificitySeriesSignal TransductionSystemTechnologyTherapeuticTimeTimeLineTissuesToxic effectTranslatingTranslationsUniversitiesValidationWaterWorkcancer imagingcancer typeclinical applicationclinically relevantcomputerized data processingcostdesigndiabeticexperiencegadolinium oxideintravenous glucose tolerance testneoplastic cellnoninvasive diagnosispatient populationpsychologicpublic health relevanceradiofrequencyresponsestatisticssugartumortumor microenvironment

项目摘要

项目成果

Peter CM Van Zijl的其他基金

相似基金

相关文献

中文摘要
翻译

英文摘要
 DESCRIPTION (provided by applicant): Cancer remains one of the leading causes of death in the industrialized world. Modern imaging technologies employ contrast agents to visualize tumor anatomy and physiology, which can provide information on malignancy and the response to treatment. Currently, all useful MRI contrast agents require some kind of chemical labeling, i.e. with paramagnetic metals or, recently, with hyperpolarized magnetic isotopes. We here propose the development of simple D-glucose as an MRI contrast agent. We will accomplish this by using the hydroxyl protons on glucose as a natural magnetic label that can be activated using specially designed series of radiofrequency (RF) pulses. This label is transferred to water and can be detected using standard MRI hardware. Some of the advantages of using a natural agent such as D-glucose at an appropriate dose are safety, absence of interference with contrast on standard anatomical images, low cost, and the ability to perform repeated studies over a short period of time. Our hypothesis is that D-glucose can be used as an infusible MRI contrast agent that provides information on two important aspects of tumor physiology, namely perfusion and permeability. We foresee that translation to clinical application will be fast since D-glucose is already widely used for other indications, such as the glucose tolerance test for diabetes, and its safety profile is well established. We have recently acquired initial data showing the MRI detectability of D-glucose at millimolar concentrations in phantoms, in animal models and in a first brain tumor patient. Our overall goal is to develop and translate to the clinc the use of D-glucose as an infusible MRI contrast agent for the combined imaging of tumor perfusion and permeability. We therefore have established engineering, biochemical and clinical aims to (i) design and optimize the MRI pulse sequence technology needed to detect D-glucose through the water signal in phantoms and animals, (ii) to translate the MRI pulse sequence methodology to human scanners, (iii) to design data analysis approaches and software packages for visualizing tumor enhancement and obtaining physiological indicators of tumor perfusion and permeability, (iv) investigate the mechanism of contrast, (v) To demonstrate the suitability of D-glucose as an MRI contrast agent for brain tumor patients first at 7T and subsequently 3T, and (vi) To optimize and standardize a clinical MRI protocol for reproducible intravenous D- glucose imaging In order to accomplish this with optimal efficiency and proper validation and to assure clinical relevance, we propose a Bioengineering Research Partnership of experts in the fields of MRI pulse sequence development, cancer biology, clinical oncology, biostatistics, and endocrinology, which will employ the facilities of several Resource Centers available at the Hugo Moser Research Institute at Kennedy Krieger and Johns Hopkins University.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Training and Dissemination
Center Administration
TRD 3: MRI parameters reflecting tissue composition and microstructure
Center Administration
海外基金